Guardant Health FDA Win Sparks Interest In Liquid Biopsy Valuation Gap

Simply Wall St.05-27

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638503333?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","is_english":true,"pubTime":"2026-05-27 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638503333","market":"sg","top_or_hot":-1,"title":"Guardant Health FDA Win Sparks Interest In Liquid Biopsy Valuation Gap","media":"Simply Wall St.","content":"<div>\n<p>Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-fda-win-sparks-interest-in-liquid-biopsy-val\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health FDA Win Sparks Interest In Liquid Biopsy Valuation Gap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health FDA Win Sparks Interest In Liquid Biopsy Valuation Gap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 16:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-fda-win-sparks-interest-in-liquid-biopsy-val><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-fda-win-sparks-interest-in-liquid-biopsy-val\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-fda-win-sparks-interest-in-liquid-biopsy-val","article_id":"2638503333","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-fda-win-sparks-interest-in-liquid-biopsy-val","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638503333","pubTimestamp":1779869401,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data.\nThe approval covers advanced cancer care and expands the test's use as a companion diagnostic across multiple cancer types.\nThe platform uses AI-enabled multiomic technology to combine genomic and epigenomic insights in a single liquid biopsy.\n\nGuardant Health focuses on liquid biopsy...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","GH":"Guardant Health Inc.","BK4551":"寇图资本持仓","BK4196":"保健护理服务","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"Guardant Health FDA获胜引发人们对液体活检估值差距的兴趣","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"GH":0.9},"content_text":"Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data. The approval covers advanced cancer care and expands the test's use as a companion diagnostic across multiple cancer types. The platform uses AI-enabled multiomic technology to combine genomic and epigenomic insights in a single liquid biopsy.  Guardant Health focuses on liquid biopsy diagnostics, aiming to make cancer testing less invasive and more broadly accessible. This new FDA approval adds an expanded version of Guardant360 Liquid CDx to its portfolio, with integrated genomic and epigenomic profiling intended for advanced cancer care. For investors tracking precision oncology tools, this development highlights that blood-based testing continues to gain regulatory traction. The FDA decision also broadens the test's potential role as a companion diagnostic, which can matter for drug selection and clinical trial design. As AI-supported multiomic approaches gain attention, the expanded Guardant360 Liquid CDx could influence how clinicians and biopharma partners think about test selection across a range of tumor types. Stay updated on the most important news stories for Guardant Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Guardant Health. NasdaqGS:GH Earnings & Revenue Growth as at May 2026 2 things going right for Guardant Health that this headline doesn't cover. AdvertisementQuick Assessment  ⚖️ Price vs Analyst Target: Guardant Health trades at US$119.85 versus an analyst target of US$131.00, which is around 8.5% below consensus. ✅ Simply Wall St Valuation: The stock is described as trading 42.8% below an estimated fair value, which flags a valuation gap. ✅ Recent Momentum: The share price is up 34.8% over the last 30 days, indicating strong short term momentum around this FDA news.  To assess whether it may be the right time to buy, sell or hold Guardant Health, you can review Simply Wall St's\ncompany report for the latest analysis of Guardant Health's fair value. Key Considerations  📊 The FDA approval of Guardant360 Liquid CDx reinforces Guardant Health's positioning in liquid biopsy for advanced cancer care. This can be relevant for long term adoption of its testing platform. 📊 Monitor how test utilization, companion diagnostic partnerships and pricing evolve, as well as how the current US$119.85 price moves relative to the US$131.00 analyst target and the 42.8% discount to estimated fair value. ⚠️ Simply Wall St highlights negative shareholders' equity and recent insider selling, so it may be useful to balance the growth narrative with scrutiny of the balance sheet and capital needs.  Dig Deeper For a more complete view, including additional risks and potential rewards, see the\ncomplete Guardant Health analysis. You can also visit the\ncommunity page for Guardant Health to review how other investors think this latest news may affect the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638503333","isCrawlerRequest":true}